G. Labat, Dr med, V. Breuil, Prof Dr, Université Côte d'Azur, Rheumatology Department, CHU de Nice, France.
M. Hayotte, P. Gerus, R. Zory, Pr, F. D'Arripe-Longueville, Pr, LAMHESS, Université Côte d'Azur, Nice, France.
J Rheumatol. 2022 Oct;49(10):1109-1116. doi: 10.3899/jrheum.220140. Epub 2022 Jun 15.
To evaluate the impact of a wearable activity tracker used to encourage physical activity, on disease flares in patients with spondyloarthritis (SpA).
This randomized controlled trial involved randomizing 108 patients with SpA into tracker and nontracker groups. The participants were then subjected to assessments of disease activity, performance (6-minute walk test), and quality of life (QOL; 36-item Short Form Health Survey) at the 12th, 24th, and 36th week. The primary outcome was the change in the frequency of flare episodes (categorized as no flare, flare in ≤ 3 days, and flare in > 3 days) between baseline and 12 weeks.
The results of the study showed that at the 12th week, the mean change (∆) of the number of flares improved in both groups: -0.32 (95% CI -0.66 to 0.02) and -0.38 (95% CI -0.68 to -0.09) in the tracker and nontracker group, respectively. However, the between-group differences were insignificant ( = 0.87). Performance scores improved in both groups at the 12th, 24th, and 36th week (all < 0.01). The different dimensions of QOL also improved at the 12th week ( < 0.01). Conversely, moderate flares ( < 0.01) and performance ( < 0.01) improved over time; however, the influence over time of a wearable activity tracker was not significant ( = 0.29 and = 0.66, respectively).
The use of a wearable activity tracker did not affect the number of flares, performance, or QOL of patients with SpA. Nevertheless, this study confirmed the benefits of physical activity on flares, disease activity, QOL, and physical performance in patients with SpA. (Move Your Spondyl "Better Live Its Rheumatism With the Physical Activity"; ClinicalTrials.gov: NCT03458026).
评估可穿戴活动追踪器对脊柱关节炎(SpA)患者疾病发作的影响。
本随机对照试验将 108 名 SpA 患者随机分为追踪器组和非追踪器组。然后,在第 12、24 和 36 周对两组患者进行疾病活动度、运动能力(6 分钟步行试验)和生活质量(36 项简明健康调查问卷)评估。主要结局为从基线到 12 周时发作频率(无发作、发作时间 ≤ 3 天和发作时间 > 3 天)的变化。
研究结果显示,第 12 周时,两组的发作次数均值变化(∆)均有所改善:追踪器组为 -0.32(95%置信区间 -0.66 至 0.02),非追踪器组为 -0.38(95%置信区间 -0.68 至 -0.09)。但两组间差异无统计学意义( = 0.87)。两组患者的运动能力评分在第 12、24 和 36 周时均有所提高(均 < 0.01)。生活质量的不同维度在第 12 周时也有所改善(均 < 0.01)。相反,中度发作(均 < 0.01)和运动能力(均 < 0.01)随时间推移而改善,但可穿戴活动追踪器的时间影响不显著(分别为 = 0.29 和 = 0.66)。
使用可穿戴活动追踪器不会影响 SpA 患者的发作次数、运动能力或生活质量。然而,本研究证实了体育活动对 SpA 患者发作、疾病活动度、生活质量和身体机能的益处。(让您的脊柱关节炎“更好地运动,更好地生活”;ClinicalTrials.gov:NCT03458026)。